IRLAB Therapeutics AB
STO:IRLAB A

Watchlist Manager
IRLAB Therapeutics AB Logo
IRLAB Therapeutics AB
STO:IRLAB A
Watchlist
Price: 1.94 SEK -0.72%
Market Cap: 164.6m SEK

Net Margin
IRLAB Therapeutics AB

-107.4%
Current
-687%
Average
4.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-107.4%
=
Net Income
-91.9m
/
Revenue
85.6m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
SE
IRLAB Therapeutics AB
STO:IRLAB A
164.8m SEK
-107%
US
Eli Lilly and Co
NYSE:LLY
999.6B USD
31%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
US
Johnson & Johnson
NYSE:JNJ
501.2B USD
27%
CH
Roche Holding AG
SIX:ROG
256.7B CHF
15%
UK
AstraZeneca PLC
LSE:AZN
210.6B GBP
16%
CH
Novartis AG
SIX:NOVN
206.2B CHF
26%
US
Merck & Co Inc
NYSE:MRK
250.5B USD
30%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
33%
IE
Endo International PLC
LSE:0Y5F
209B USD
-126%
US
Pfizer Inc
NYSE:PFE
142.4B USD
16%
No Stocks Found

IRLAB Therapeutics AB
Glance View

Market Cap
164.8m SEK
Industry
Pharmaceuticals

IRLAB Therapeutics AB engages in the provision of novel treatments for disorders of the brain that focuses on illness in the central nervous system. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2017-02-28. The company focuses on illnesses in the central nervous system and primarily on development of drugs to assist patients with Parkinson’s disease. The firm possesses a research platform Integrative Screening Process (ISP), which aims to discover and develop drug candidates for the treatment of brain diseases. The firm operates projects on both clinical phase and preclinical phases. The primary projects are IRL790 and IRL752, both on clinical phase. The IRL790 project is a psychomotor stabilizer for the treatment of levodopa (L-dopa) amino acid that dyskinesia induces in Parkinson’s Disease (PD-LIDs) and Parkinson Disease psychosis (PD-Psychosis). The IRL752 project aims at cortical enhancement for the treatment of Parkinson Disease Dementia (PD-D) and Behavioral and Psychological Symptoms of Dementia (BPSD).

IRLAB A Intrinsic Value
9.01 SEK
Undervaluation 78%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-107.4%
=
Net Income
-91.9m
/
Revenue
85.6m
What is the Net Margin of IRLAB Therapeutics AB?

Based on IRLAB Therapeutics AB's most recent financial statements, the company has Net Margin of -107.4%.

Back to Top